Single Oral Challenge by Advanced Glycation End Products Acutely Impairs Endothelial Function in Diabetic and Nondiabetic Subjects
OBJECTIVE:--The current study was designed to test the acute effects of dietary advanced glycation end products (AGEs) on endothelial function of diabetic and nondiabetic subjects. RESEARCH DESIGN AND METHODS--Flow-mediated dilation (FMD) of the brachial artery and serum levels of AGEs, plasminogen...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2007-10, Vol.30 (10), p.2579-2582 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2582 |
|---|---|
| container_issue | 10 |
| container_start_page | 2579 |
| container_title | Diabetes care |
| container_volume | 30 |
| creator | Uribarri, Jaime Stirban, Alin Sander, Denise Cai, Weijing Negrean, Monica Buenting, Cristina E Koschinsky, Theodore Vlassara, Helen |
| description | OBJECTIVE:--The current study was designed to test the acute effects of dietary advanced glycation end products (AGEs) on endothelial function of diabetic and nondiabetic subjects. RESEARCH DESIGN AND METHODS--Flow-mediated dilation (FMD) of the brachial artery and serum levels of AGEs, plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion molecule 1 (VCAM-1), and glucose were assessed before and after a single oral AGE challenge (~1.8 x 10⁶ AGE units) in 44 diabetic and 10 nondiabetic subjects. RESULTS:--The diabetic patients had higher baseline levels of serum AGEs (P = 0.020), PAI-1 (NS), and VCAM-1 (P = 0.033) and lower baseline values of FMD compared with nondiabetic subjects (P = 0.032). Ninety minutes after a single oral AGE challenge, serum AGEs and PAI-1 levels increased and FMD decreased significantly in both healthy subjects (AGEs: 7.2 ± 0.5 to 9.3 ± 1 units/ml, P = 0.014; PAI-1: 5.4 ± 0.4 to 6.8 ± 0.4 ng/ml, P = 0.007; and FMD: 9.9 ± 0.7 to 7.4 ± 0.9%, P = 0.019) and diabetic subjects (AGEs: 10.5 ± 0.7 to 14.2 ± 1 units/ml, P = 0.020; PAI-1: 6.5 ± 1 to 10 ± 2 ng/ml, P = 0.030; and FMD: 5.4 ± 0.4 to 4.0 ± 0.3%, P = 0.032). Serum glucose and VCAM-1 levels remained unchanged. CONCLUSIONS:--Significant increases in serum AGEs can occur together with altered clinical measures of endothelial function in diabetic and nondiabetic subjects after a single modest AGE-rich beverage. Thus, repeated or chronic exposure to high AGE diets could over time lead to and/or accelerate vascular disease. |
| doi_str_mv | 10.2337/dc07-0320 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_223026511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A169924085</galeid><sourcerecordid>A169924085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c578t-de64078af3c59066bcf3094d22971af8351f2f2189712c64bdf48c87ea5dc5543</originalsourceid><addsrcrecordid>eNptkV-L1DAUxYso7jj64BfQIiiIdM2_tunjMO6uC4srjPsc0uSmkyGTjkmrzKuf3HQ7siBLHpJ78zuXyzlZ9hqjc0Jp_VkrVBeIEvQkW-CGlkVZMv40WyDMmqJsGnKWvYhxhxBijPPn2RmuWVMRyhfZn431nYP8NkiXr7fSOfAd5O0xX-lf0ivQ-ZU7KjnY3ucXXuffQ69HNcR8pcYB3DG_3h-kDXH67IctOJsGXY5e3Susz79Y2cJgVS6T-lvv9b96M7Y7SJNeZs-MdBFene5ldnd58WP9tbi5vbper24KVdZ8KDRUDNVcGqrKBlVVqwxFDdOENDWWhtMSG2II5qkkqmKtNowrXoMstUqG0GX2YZ57CP3PEeIg9jYqcE566McoKk5JzZN_y-zdf-CuH4NPuwlCKCJViXGCihnqpANhvemHIFUHHpKTvQdjU3uFq-Q-Q7xM_PkjfDoa9lY9Kvg4C1ToYwxgxCHYvQxHgZGYYhdT7GKKPbFvThuP7R70A3nKOQHvT4CMSjoTUrQ2PnANZpjXNHGfZm5ru-1vG0DMcUGcHkqmBkX3C5T1ZNTbmTayF7ILaeLdhiBMEeIYVaimfwFQTcuJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223026511</pqid></control><display><type>article</type><title>Single Oral Challenge by Advanced Glycation End Products Acutely Impairs Endothelial Function in Diabetic and Nondiabetic Subjects</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Uribarri, Jaime ; Stirban, Alin ; Sander, Denise ; Cai, Weijing ; Negrean, Monica ; Buenting, Cristina E ; Koschinsky, Theodore ; Vlassara, Helen</creator><creatorcontrib>Uribarri, Jaime ; Stirban, Alin ; Sander, Denise ; Cai, Weijing ; Negrean, Monica ; Buenting, Cristina E ; Koschinsky, Theodore ; Vlassara, Helen</creatorcontrib><description>OBJECTIVE:--The current study was designed to test the acute effects of dietary advanced glycation end products (AGEs) on endothelial function of diabetic and nondiabetic subjects. RESEARCH DESIGN AND METHODS--Flow-mediated dilation (FMD) of the brachial artery and serum levels of AGEs, plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion molecule 1 (VCAM-1), and glucose were assessed before and after a single oral AGE challenge (~1.8 x 10⁶ AGE units) in 44 diabetic and 10 nondiabetic subjects. RESULTS:--The diabetic patients had higher baseline levels of serum AGEs (P = 0.020), PAI-1 (NS), and VCAM-1 (P = 0.033) and lower baseline values of FMD compared with nondiabetic subjects (P = 0.032). Ninety minutes after a single oral AGE challenge, serum AGEs and PAI-1 levels increased and FMD decreased significantly in both healthy subjects (AGEs: 7.2 ± 0.5 to 9.3 ± 1 units/ml, P = 0.014; PAI-1: 5.4 ± 0.4 to 6.8 ± 0.4 ng/ml, P = 0.007; and FMD: 9.9 ± 0.7 to 7.4 ± 0.9%, P = 0.019) and diabetic subjects (AGEs: 10.5 ± 0.7 to 14.2 ± 1 units/ml, P = 0.020; PAI-1: 6.5 ± 1 to 10 ± 2 ng/ml, P = 0.030; and FMD: 5.4 ± 0.4 to 4.0 ± 0.3%, P = 0.032). Serum glucose and VCAM-1 levels remained unchanged. CONCLUSIONS:--Significant increases in serum AGEs can occur together with altered clinical measures of endothelial function in diabetic and nondiabetic subjects after a single modest AGE-rich beverage. Thus, repeated or chronic exposure to high AGE diets could over time lead to and/or accelerate vascular disease.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc07-0320</identifier><identifier>PMID: 17496238</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>ACE inhibitors ; Administration, Oral ; Biological and medical sciences ; Blood circulation disorders ; Cardiovascular disease ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - physiopathology ; Cell adhesion & migration ; Data analysis ; Diabetes ; Diabetes Mellitus - physiopathology ; Diabetes. Impaired glucose tolerance ; Diabetic Angiopathies - blood ; Diabetic Angiopathies - physiopathology ; Diabetic retinopathy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiology ; Endothelium, Vascular - physiopathology ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Glycation End Products, Advanced - administration & dosage ; Glycation End Products, Advanced - blood ; Glycation End Products, Advanced - pharmacology ; Human subjects ; Humans ; Hyperglycemia ; Medical sciences ; Metabolic diseases ; Miscellaneous ; Monoclonal antibodies ; Mortality ; Patients ; Plasminogen Activator Inhibitor 1 - blood ; Properties ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Reference Values ; Risk factors ; Studies ; Vascular endothelium ; Vein & artery diseases</subject><ispartof>Diabetes care, 2007-10, Vol.30 (10), p.2579-2582</ispartof><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2007 American Diabetes Association</rights><rights>Copyright American Diabetes Association Oct 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c578t-de64078af3c59066bcf3094d22971af8351f2f2189712c64bdf48c87ea5dc5543</citedby><cites>FETCH-LOGICAL-c578t-de64078af3c59066bcf3094d22971af8351f2f2189712c64bdf48c87ea5dc5543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19141873$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17496238$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uribarri, Jaime</creatorcontrib><creatorcontrib>Stirban, Alin</creatorcontrib><creatorcontrib>Sander, Denise</creatorcontrib><creatorcontrib>Cai, Weijing</creatorcontrib><creatorcontrib>Negrean, Monica</creatorcontrib><creatorcontrib>Buenting, Cristina E</creatorcontrib><creatorcontrib>Koschinsky, Theodore</creatorcontrib><creatorcontrib>Vlassara, Helen</creatorcontrib><title>Single Oral Challenge by Advanced Glycation End Products Acutely Impairs Endothelial Function in Diabetic and Nondiabetic Subjects</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>OBJECTIVE:--The current study was designed to test the acute effects of dietary advanced glycation end products (AGEs) on endothelial function of diabetic and nondiabetic subjects. RESEARCH DESIGN AND METHODS--Flow-mediated dilation (FMD) of the brachial artery and serum levels of AGEs, plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion molecule 1 (VCAM-1), and glucose were assessed before and after a single oral AGE challenge (~1.8 x 10⁶ AGE units) in 44 diabetic and 10 nondiabetic subjects. RESULTS:--The diabetic patients had higher baseline levels of serum AGEs (P = 0.020), PAI-1 (NS), and VCAM-1 (P = 0.033) and lower baseline values of FMD compared with nondiabetic subjects (P = 0.032). Ninety minutes after a single oral AGE challenge, serum AGEs and PAI-1 levels increased and FMD decreased significantly in both healthy subjects (AGEs: 7.2 ± 0.5 to 9.3 ± 1 units/ml, P = 0.014; PAI-1: 5.4 ± 0.4 to 6.8 ± 0.4 ng/ml, P = 0.007; and FMD: 9.9 ± 0.7 to 7.4 ± 0.9%, P = 0.019) and diabetic subjects (AGEs: 10.5 ± 0.7 to 14.2 ± 1 units/ml, P = 0.020; PAI-1: 6.5 ± 1 to 10 ± 2 ng/ml, P = 0.030; and FMD: 5.4 ± 0.4 to 4.0 ± 0.3%, P = 0.032). Serum glucose and VCAM-1 levels remained unchanged. CONCLUSIONS:--Significant increases in serum AGEs can occur together with altered clinical measures of endothelial function in diabetic and nondiabetic subjects after a single modest AGE-rich beverage. Thus, repeated or chronic exposure to high AGE diets could over time lead to and/or accelerate vascular disease.</description><subject>ACE inhibitors</subject><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Blood circulation disorders</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - physiopathology</subject><subject>Cell adhesion & migration</subject><subject>Data analysis</subject><subject>Diabetes</subject><subject>Diabetes Mellitus - physiopathology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Angiopathies - blood</subject><subject>Diabetic Angiopathies - physiopathology</subject><subject>Diabetic retinopathy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiology</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Glycation End Products, Advanced - administration & dosage</subject><subject>Glycation End Products, Advanced - blood</subject><subject>Glycation End Products, Advanced - pharmacology</subject><subject>Human subjects</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Miscellaneous</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Patients</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Properties</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Reference Values</subject><subject>Risk factors</subject><subject>Studies</subject><subject>Vascular endothelium</subject><subject>Vein & artery diseases</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkV-L1DAUxYso7jj64BfQIiiIdM2_tunjMO6uC4srjPsc0uSmkyGTjkmrzKuf3HQ7siBLHpJ78zuXyzlZ9hqjc0Jp_VkrVBeIEvQkW-CGlkVZMv40WyDMmqJsGnKWvYhxhxBijPPn2RmuWVMRyhfZn431nYP8NkiXr7fSOfAd5O0xX-lf0ivQ-ZU7KjnY3ucXXuffQ69HNcR8pcYB3DG_3h-kDXH67IctOJsGXY5e3Susz79Y2cJgVS6T-lvv9b96M7Y7SJNeZs-MdBFene5ldnd58WP9tbi5vbper24KVdZ8KDRUDNVcGqrKBlVVqwxFDdOENDWWhtMSG2II5qkkqmKtNowrXoMstUqG0GX2YZ57CP3PEeIg9jYqcE566McoKk5JzZN_y-zdf-CuH4NPuwlCKCJViXGCihnqpANhvemHIFUHHpKTvQdjU3uFq-Q-Q7xM_PkjfDoa9lY9Kvg4C1ToYwxgxCHYvQxHgZGYYhdT7GKKPbFvThuP7R70A3nKOQHvT4CMSjoTUrQ2PnANZpjXNHGfZm5ru-1vG0DMcUGcHkqmBkX3C5T1ZNTbmTayF7ILaeLdhiBMEeIYVaimfwFQTcuJ</recordid><startdate>20071001</startdate><enddate>20071001</enddate><creator>Uribarri, Jaime</creator><creator>Stirban, Alin</creator><creator>Sander, Denise</creator><creator>Cai, Weijing</creator><creator>Negrean, Monica</creator><creator>Buenting, Cristina E</creator><creator>Koschinsky, Theodore</creator><creator>Vlassara, Helen</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20071001</creationdate><title>Single Oral Challenge by Advanced Glycation End Products Acutely Impairs Endothelial Function in Diabetic and Nondiabetic Subjects</title><author>Uribarri, Jaime ; Stirban, Alin ; Sander, Denise ; Cai, Weijing ; Negrean, Monica ; Buenting, Cristina E ; Koschinsky, Theodore ; Vlassara, Helen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c578t-de64078af3c59066bcf3094d22971af8351f2f2189712c64bdf48c87ea5dc5543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>ACE inhibitors</topic><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Blood circulation disorders</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - physiopathology</topic><topic>Cell adhesion & migration</topic><topic>Data analysis</topic><topic>Diabetes</topic><topic>Diabetes Mellitus - physiopathology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Angiopathies - blood</topic><topic>Diabetic Angiopathies - physiopathology</topic><topic>Diabetic retinopathy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiology</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Glycation End Products, Advanced - administration & dosage</topic><topic>Glycation End Products, Advanced - blood</topic><topic>Glycation End Products, Advanced - pharmacology</topic><topic>Human subjects</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Miscellaneous</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Patients</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Properties</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Reference Values</topic><topic>Risk factors</topic><topic>Studies</topic><topic>Vascular endothelium</topic><topic>Vein & artery diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uribarri, Jaime</creatorcontrib><creatorcontrib>Stirban, Alin</creatorcontrib><creatorcontrib>Sander, Denise</creatorcontrib><creatorcontrib>Cai, Weijing</creatorcontrib><creatorcontrib>Negrean, Monica</creatorcontrib><creatorcontrib>Buenting, Cristina E</creatorcontrib><creatorcontrib>Koschinsky, Theodore</creatorcontrib><creatorcontrib>Vlassara, Helen</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uribarri, Jaime</au><au>Stirban, Alin</au><au>Sander, Denise</au><au>Cai, Weijing</au><au>Negrean, Monica</au><au>Buenting, Cristina E</au><au>Koschinsky, Theodore</au><au>Vlassara, Helen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single Oral Challenge by Advanced Glycation End Products Acutely Impairs Endothelial Function in Diabetic and Nondiabetic Subjects</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2007-10-01</date><risdate>2007</risdate><volume>30</volume><issue>10</issue><spage>2579</spage><epage>2582</epage><pages>2579-2582</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>OBJECTIVE:--The current study was designed to test the acute effects of dietary advanced glycation end products (AGEs) on endothelial function of diabetic and nondiabetic subjects. RESEARCH DESIGN AND METHODS--Flow-mediated dilation (FMD) of the brachial artery and serum levels of AGEs, plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion molecule 1 (VCAM-1), and glucose were assessed before and after a single oral AGE challenge (~1.8 x 10⁶ AGE units) in 44 diabetic and 10 nondiabetic subjects. RESULTS:--The diabetic patients had higher baseline levels of serum AGEs (P = 0.020), PAI-1 (NS), and VCAM-1 (P = 0.033) and lower baseline values of FMD compared with nondiabetic subjects (P = 0.032). Ninety minutes after a single oral AGE challenge, serum AGEs and PAI-1 levels increased and FMD decreased significantly in both healthy subjects (AGEs: 7.2 ± 0.5 to 9.3 ± 1 units/ml, P = 0.014; PAI-1: 5.4 ± 0.4 to 6.8 ± 0.4 ng/ml, P = 0.007; and FMD: 9.9 ± 0.7 to 7.4 ± 0.9%, P = 0.019) and diabetic subjects (AGEs: 10.5 ± 0.7 to 14.2 ± 1 units/ml, P = 0.020; PAI-1: 6.5 ± 1 to 10 ± 2 ng/ml, P = 0.030; and FMD: 5.4 ± 0.4 to 4.0 ± 0.3%, P = 0.032). Serum glucose and VCAM-1 levels remained unchanged. CONCLUSIONS:--Significant increases in serum AGEs can occur together with altered clinical measures of endothelial function in diabetic and nondiabetic subjects after a single modest AGE-rich beverage. Thus, repeated or chronic exposure to high AGE diets could over time lead to and/or accelerate vascular disease.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>17496238</pmid><doi>10.2337/dc07-0320</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2007-10, Vol.30 (10), p.2579-2582 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_proquest_journals_223026511 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | ACE inhibitors Administration, Oral Biological and medical sciences Blood circulation disorders Cardiovascular disease Cardiovascular Diseases - blood Cardiovascular Diseases - physiopathology Cell adhesion & migration Data analysis Diabetes Diabetes Mellitus - physiopathology Diabetes. Impaired glucose tolerance Diabetic Angiopathies - blood Diabetic Angiopathies - physiopathology Diabetic retinopathy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Endothelium, Vascular - drug effects Endothelium, Vascular - physiology Endothelium, Vascular - physiopathology Etiopathogenesis. Screening. Investigations. Target tissue resistance Glycation End Products, Advanced - administration & dosage Glycation End Products, Advanced - blood Glycation End Products, Advanced - pharmacology Human subjects Humans Hyperglycemia Medical sciences Metabolic diseases Miscellaneous Monoclonal antibodies Mortality Patients Plasminogen Activator Inhibitor 1 - blood Properties Public health. Hygiene Public health. Hygiene-occupational medicine Reference Values Risk factors Studies Vascular endothelium Vein & artery diseases |
| title | Single Oral Challenge by Advanced Glycation End Products Acutely Impairs Endothelial Function in Diabetic and Nondiabetic Subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A59%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single%20Oral%20Challenge%20by%20Advanced%20Glycation%20End%20Products%20Acutely%20Impairs%20Endothelial%20Function%20in%20Diabetic%20and%20Nondiabetic%20Subjects&rft.jtitle=Diabetes%20care&rft.au=Uribarri,%20Jaime&rft.date=2007-10-01&rft.volume=30&rft.issue=10&rft.spage=2579&rft.epage=2582&rft.pages=2579-2582&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc07-0320&rft_dat=%3Cgale_proqu%3EA169924085%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223026511&rft_id=info:pmid/17496238&rft_galeid=A169924085&rfr_iscdi=true |